RT Journal Article
SR Electronic
T1 Enhanced mindfulness based stress reduction (MBSR+) in episodic migraine: a randomized clinical trial with MRI outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19004069
DO 10.1101/19004069
A1 Seminowicz, David A.
A1 Burrowes, Shana AB
A1 Kearson, Alexandra
A1 Zhang, Jing
A1 Krimmel, Samuel R
A1 Samawi, Luma
A1 Furman, Andrew J
A1 Keaser, Michael L
A1 Gould, Neda F.
A1 Magyari, Tirsh
A1 White, Linda
A1 Goloubeva, Olga
A1 Goyal, Madhav
A1 Peterlin, B. Lee
A1 Haythornthwaite, Jennifer A.
YR 2019
UL http://medrxiv.org/content/early/2019/08/06/19004069.abstract
AB Background Mindfulness interventions have not been rigorously evaluated in episodic migraine.Objective To evaluate the efficacy of an enhanced mindfulness based stress reduction (MBSR+) versus stress management for headache (SMH).Design, Setting, Participants Randomized, assessor-blind, clinical trial of 98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n=50) to SMH (n=48). (https://clinicaltrials.gov/ct2/show/NCT02133209)Intervention MBSR+ and SMH were delivered weekly by group for 8 weeks, then bi-weekly for another 8 weeks.Measurements The primary outcome was reduction in headache days from baseline to 20 weeks. MRI outcomes included activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula (daINS) to DLPFC and cognitive task network, and gray matter volume of DLPFC, daINS, and anterior midcingulate. Secondary outcomes were headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses.Results Reduction in headache days from baseline to 20 weeks was greater for MBSR+ (7.8 [95%CI, 6.9-8.8] to 4.6 [95%CI, 3.7-5.6]) than for SMH (7.7 [95%CI 6.7-8.7] to 6.0 [95%CI, 4.9-7.0]) (P=0.04). 52% of the MBSR+ group showed a response to treatment (50% reduction in headache days) compared with 23% in the SMH group (P=0.004). Reduction in headache-related disability was greater for MBSR+ (59.6 [95%CI, 57.9-61.3] to 54.6 [95%CI, 52.9-56.4]) than SMH (59.6 [95%CI, 57.7-61.5] to 57.5 [95%CI, 55.5-59.4]) (P=0.02). There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed.Limitations A single site and likely self-selection bias.Conclusions MBSR+ is an effective treatment option for episodic migraine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02133209Funding StatementNCCIH/NIH R01 AT007176Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAvailable upon request from corresponding author